This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Simulations Plus Reports FY2012 And Fourth Quarter FY2012 Financial Results

Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of software for pharmaceutical discovery and development, today reported its financial results for its 2012 fiscal year (FY12) and fourth quarter (4Q12) ended August 31, 2012. The former Words+ subsidiary was sold on November 30, 2011, therefore results provided in this press release and in our annual report treat Words+ as discontinued operations and are based on the performance of the ongoing pharmaceutical software and services business.

Results for the 2012 fiscal year (FY12):
  • Revenues were $9.45 million, representing an increase of 8.1% over $8.74 million in FY11
  • SG&A expense increased 6.1% to $3.38 million from $3.19 million in FY11
    • As a percent of sales, SG&A decreased to 35.8% from 36.5% in FY11
  • R&D expense was $0.947 million, an increase of 104% over $0.464 million in FY11
    • This increase was due to investments in expanding our scientific staff and in our malaria project
  • Net income was $3.03 million, representing an increase of 11.5% over $2.71 million in FY11
  • Net income per fully diluted share was $0.187, representing an increase of 11.1% over $0.169 for FY11
  • Cash increased to $12.7 million, representing an increase of 24.8% from $10.2 million at the end of FY11
    • This was in spite of dividend distributions to shareholders of nearly $2.4 million
  • Shareholders’ equity increased to $15.1 million, representing an increase of 7.9% from $14.0 million at the end of FY11

Results for the fourth quarter FY12 (4Q12):
  • Revenues were $1.64 million, representing an increase of 14.9% over $1.43 million in 4Q11
  • SG&A decreased 14.5% to $0.831 million from $0.973 million in FY11
  • R&D expense was $0.203 million, an increase of 462.0% from $0.036 million in FY11
    • This increase was due to investments in expanding our scientific staff and in our malaria project
  • Net income was $0.349 million, representing an increase of 88.1% over $0.186 million in FY11
  • Earnings per fully diluted share were $0.021, representing an increase of 85.4% over $0.012 in 4Q11

Ms. Momoko Beran, chief financial officer for Simulations Plus, said: “We completed another record fiscal year, with all four quarters setting new quarterly records. Earnings per share increased by more than 11% - the direct result of a strong performance from our pharmaceutical software and services business. R&D expenses increased because we have increased our scientific staff, increased salaries for existing staff, and because of outside expenses incurred through our investment in our malaria project. SG&A increased 6.1% primarily because we now pay the entire office lease following the sale of Words+ on November 30, 2011. Words+ pays 20% of the lease, however it is reported as other income rather than offsetting the lease expense. Other increases in SG&A were advertising, trade shows, marketing labor as we attended more trade shows and conferences, insurance (health/dental, directors and officers), and increased legal fees incurred during our due diligence activities for the unsuccessful attempted acquisition of Entelos in bankruptcy court.”

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,102.38 -272.38 -1.66%
S&P 500 1,921.22 -29.91 -1.53%
NASDAQ 4,683.9190 -49.5780 -1.05%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs